Corcept Therapeutics Incorporated (0I3Q.L)
USD 67.86
(2.8%)
USD 67.86
(2.8%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 106.14 Million USD | 4.66% |
| 2022 | 101.41 Million USD | -9.86% |
| 2021 | 112.51 Million USD | 6.13% |
| 2020 | 106.01 Million USD | 12.56% |
| 2019 | 94.18 Million USD | 24.89% |
| 2018 | 75.41 Million USD | -41.6% |
| 2017 | 129.12 Million USD | 1486.27% |
| 2016 | 8.14 Million USD | 227.03% |
| 2015 | -6.4 Million USD | 79.58% |
| 2014 | -31.38 Million USD | 31.79% |
| 2013 | -46.01 Million USD | -20.93% |
| 2012 | -38.04 Million USD | -17.6% |
| 2011 | -32.35 Million USD | -24.6% |
| 2010 | -25.96 Million USD | -28.76% |
| 2009 | -20.16 Million USD | -0.52% |
| 2008 | -20.06 Million USD | -73.34% |
| 2007 | -11.57 Million USD | 53.47% |
| 2006 | -24.87 Million USD | -23.79% |
| 2005 | -20.09 Million USD | -29.34% |
| 2004 | -15.53 Million USD | -58.32% |
| 2003 | -9.81 Million USD | 46.97% |
| 2002 | -18.5 Million USD | -148.24% |
| 2001 | -7.45 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 27.76 Million USD | -11.46% |
| 2024 Q2 | 35.48 Million USD | 27.83% |
| 2024 Q3 | 47.21 Million USD | 31.57% |
| 2023 Q3 | 31.37 Million USD | 13.99% |
| 2023 Q1 | 15.87 Million USD | -4.35% |
| 2023 FY | 106.14 Million USD | 4.66% |
| 2023 Q2 | 27.52 Million USD | 73.36% |
| 2023 Q4 | 31.35 Million USD | -0.07% |
| 2022 Q3 | 34.6 Million USD | 26.25% |
| 2022 Q1 | 22.79 Million USD | -28.88% |
| 2022 Q4 | 16.6 Million USD | -52.03% |
| 2022 FY | 101.41 Million USD | -9.86% |
| 2022 Q2 | 27.41 Million USD | 20.24% |
| 2021 Q4 | 32.05 Million USD | 5.19% |
| 2021 Q3 | 30.47 Million USD | 14.89% |
| 2021 Q2 | 26.52 Million USD | 13.03% |
| 2021 FY | 112.51 Million USD | 6.13% |
| 2021 Q1 | 23.46 Million USD | -9.73% |
| 2020 FY | 106.01 Million USD | 12.56% |
| 2020 Q3 | 21.62 Million USD | -23.66% |
| 2020 Q2 | 28.32 Million USD | -5.78% |
| 2020 Q1 | 30.06 Million USD | 2.33% |
| 2020 Q4 | 25.99 Million USD | 20.2% |
| 2019 FY | 94.18 Million USD | 24.89% |
| 2019 Q2 | 20.18 Million USD | 10.46% |
| 2019 Q1 | 18.27 Million USD | -16.97% |
| 2019 Q4 | 29.38 Million USD | 11.55% |
| 2019 Q3 | 26.34 Million USD | 30.49% |
| 2018 Q4 | 22 Million USD | 24.01% |
| 2018 FY | 75.41 Million USD | -41.6% |
| 2018 Q2 | 18.19 Million USD | 4.22% |
| 2018 Q3 | 17.74 Million USD | -2.47% |
| 2018 Q1 | 17.45 Million USD | -82.24% |
| 2017 Q4 | 98.33 Million USD | 614.76% |
| 2017 Q2 | 12.64 Million USD | 188.22% |
| 2017 Q3 | 13.75 Million USD | 8.78% |
| 2017 FY | 129.12 Million USD | 1486.27% |
| 2017 Q1 | 4.38 Million USD | -4.55% |
| 2016 Q1 | -19 Thousand USD | -101.98% |
| 2016 Q2 | 977 Thousand USD | 5242.11% |
| 2016 Q3 | 2.58 Million USD | 164.59% |
| 2016 Q4 | 4.59 Million USD | 77.83% |
| 2016 FY | 8.14 Million USD | 227.03% |
| 2015 Q3 | -601 Thousand USD | 68.96% |
| 2015 Q4 | 959 Thousand USD | 259.57% |
| 2015 Q2 | -1.93 Million USD | 59.92% |
| 2015 FY | -6.4 Million USD | 79.58% |
| 2015 Q1 | -4.83 Million USD | -24.01% |
| 2014 Q2 | -7.55 Million USD | 45.79% |
| 2014 Q3 | -6 Million USD | 20.47% |
| 2014 FY | -31.38 Million USD | 31.79% |
| 2014 Q4 | -3.89 Million USD | 35.15% |
| 2014 Q1 | -13.93 Million USD | -25.22% |
| 2013 Q2 | -11.89 Million USD | 1.55% |
| 2013 FY | -46.01 Million USD | -20.93% |
| 2013 Q4 | -11.12 Million USD | -2.0% |
| 2013 Q3 | -10.9 Million USD | 8.33% |
| 2013 Q1 | -12.08 Million USD | -8.63% |
| 2012 Q3 | -8.29 Million USD | -9.16% |
| 2012 Q2 | -7.59 Million USD | 31.15% |
| 2012 FY | -38.04 Million USD | -17.6% |
| 2012 Q1 | -11.03 Million USD | -11.05% |
| 2012 Q4 | -11.12 Million USD | -34.14% |
| 2011 Q2 | -8.88 Million USD | -25.08% |
| 2011 FY | -32.35 Million USD | -24.6% |
| 2011 Q1 | -7.1 Million USD | -0.11% |
| 2011 Q4 | -9.93 Million USD | -54.41% |
| 2011 Q3 | -6.43 Million USD | 27.55% |
| 2010 Q4 | -7.09 Million USD | 0.15% |
| 2010 FY | -25.96 Million USD | -28.76% |
| 2010 Q3 | -7.1 Million USD | -24.74% |
| 2010 Q2 | -5.69 Million USD | 6.22% |
| 2010 Q1 | -6.07 Million USD | -17.47% |
| 2009 Q4 | -5.17 Million USD | -10.75% |
| 2009 FY | -20.16 Million USD | -0.52% |
| 2009 Q3 | -4.66 Million USD | 4.31% |
| 2009 Q2 | -4.87 Million USD | 10.5% |
| 2009 Q1 | -5.45 Million USD | 11.68% |
| 2008 Q3 | -5.56 Million USD | -26.59% |
| 2008 Q2 | -4.39 Million USD | -11.86% |
| 2008 Q1 | -3.93 Million USD | 6.27% |
| 2008 FY | -20.06 Million USD | -73.34% |
| 2008 Q4 | -6.17 Million USD | -10.89% |
| 2007 Q3 | -3.42 Million USD | -141.92% |
| 2007 Q4 | -4.19 Million USD | -22.32% |
| 2007 FY | -11.57 Million USD | 53.47% |
| 2007 Q1 | -2.53 Million USD | 34.61% |
| 2007 Q2 | -1.41 Million USD | 44.1% |
| 2006 Q3 | -6.4 Million USD | 18.58% |
| 2006 Q2 | -7.86 Million USD | -16.85% |
| 2006 Q4 | -3.87 Million USD | 39.45% |
| 2006 Q1 | -6.73 Million USD | -28.26% |
| 2006 FY | -24.87 Million USD | -23.79% |
| 2005 Q3 | -5.22 Million USD | -27.05% |
| 2005 Q1 | -5.51 Million USD | -3.78% |
| 2005 FY | -20.09 Million USD | -29.34% |
| 2005 Q4 | -5.24 Million USD | -0.46% |
| 2005 Q2 | -4.11 Million USD | 25.42% |
| 2004 Q4 | -5.31 Million USD | -29.89% |
| 2004 FY | -15.53 Million USD | -58.32% |
| 2004 Q2 | -3.58 Million USD | -40.49% |
| 2004 Q3 | -4.08 Million USD | -14.09% |
| 2004 Q1 | -2.55 Million USD | -28.22% |
| 2003 Q2 | -2.88 Million USD | -2.49% |
| 2003 Q4 | -1.98 Million USD | 6.57% |
| 2003 Q3 | -2.12 Million USD | 26.1% |
| 2003 FY | -9.81 Million USD | 46.97% |
| 2003 Q1 | -2.81 Million USD | 0.0% |
| 2002 FY | -18.5 Million USD | -148.24% |
| 2001 FY | -7.45 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 98.23% |
| Dynavax Technologies Corporation | -6.38 Million USD | 1761.293% |
| Illumina, Inc. | -1.16 Billion USD | 109.142% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 92.184% |
| Biogen Inc. | 1.16 Billion USD | 90.859% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 123.903% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 86.544% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 119.803% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -7965.35% |
| Waters Corporation | 642.23 Million USD | 83.473% |
| Perrigo Company plc | -12.7 Million USD | 935.748% |
| uniQure N.V. | -308.47 Million USD | 134.408% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 130.146% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 170.021% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 138.439% |
| bluebird bio, Inc. | -211.91 Million USD | 150.087% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 189.56% |
| Imunon, Inc. | -19.51 Million USD | 643.89% |
| Myriad Genetics, Inc. | -112 Million USD | 194.768% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 57.493% |
| Nektar Therapeutics | -276.05 Million USD | 138.449% |
| Editas Medicine, Inc. | -153.21 Million USD | 169.273% |
| Verastem, Inc. | -87.36 Million USD | 221.488% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 101.229% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 337.964% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 196.003% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 366.282% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 36.688% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 141.167% |
| Evolus, Inc. | -61.68 Million USD | 272.068% |
| Adicet Bio, Inc. | -142.65 Million USD | 174.402% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 219.958% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 97.315% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 150.724% |
| FibroGen, Inc. | -284.23 Million USD | 137.343% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 91.44% |
| OPKO Health, Inc. | -188.86 Million USD | 156.199% |
| Homology Medicines, Inc. | -53.74 Million USD | 297.495% |
| Geron Corporation | -184.12 Million USD | 157.645% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 124.109% |
| Exelixis, Inc. | 207.76 Million USD | 48.913% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 223.569% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 323.429% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 122.058% |
| Zoetis Inc. | 2.34 Billion USD | 95.472% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 144.366% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 295.874% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 97.068% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 351.523% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 128.977% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 62.307% |
| Blueprint Medicines Corporation | -506.98 Million USD | 120.936% |
| Insmed Incorporated | -749.56 Million USD | 114.16% |
| TG Therapeutics, Inc. | 12.67 Million USD | -737.595% |
| Incyte Corporation | 597.59 Million USD | 82.239% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 113.957% |